186 related articles for article (PubMed ID: 34305008)
21. Shorter turn-around-time and improved patient care in peripheral blood progenitor cell collection procedures.
Ratcliffe N; Blume C; John P; Weiss T; Hubbell C; Henry JB
J Clin Apher; 1999; 14(1):35-41. PubMed ID: 10355662
[TBL] [Abstract][Full Text] [Related]
22. Implementation of a quality system (ISO 9000 series) for placental blood banking.
Sirchia G; Rebulla P; Lecchi L; Mozzi F; Crepaldi R; Parravicini A
J Hematother; 1998 Feb; 7(1):19-35. PubMed ID: 9507378
[TBL] [Abstract][Full Text] [Related]
23. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P
Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287
[TBL] [Abstract][Full Text] [Related]
24. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.
Reed W; Noga SJ; Gee AP; Rooney CM; Wagner JE; McCullough J; McKenna DH; Whiteside TL; Donnenberg AD; Baker AK; Lindblad RW; Wagner EL; Mondoro TH
Transfusion; 2009 Apr; 49(4):786-96. PubMed ID: 19170985
[TBL] [Abstract][Full Text] [Related]
25. Obtaining an accepted Investigational New Drug application to operate an umbilical cord blood bank.
Reems JA; Fujita D; Tyler T; Moldwin R; Smith SD
Transfusion; 1999 Apr; 39(4):357-63. PubMed ID: 10220260
[TBL] [Abstract][Full Text] [Related]
26. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.
Yim R
Transfusion; 2005 Oct; 45(4 Suppl):144S-58S. PubMed ID: 16181400
[TBL] [Abstract][Full Text] [Related]
27. A multicenter evaluation of heterogeneity in cellular therapy processing laboratory procedure times to assess workload capacity.
Thibodeaux SR; McKenna DH; Szczepiorkowski ZM; Fontaine MJ; Kelley L; Reems JA; Young PP;
Transfusion; 2020 Aug; 60(8):1811-1820. PubMed ID: 32654200
[TBL] [Abstract][Full Text] [Related]
28. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
29. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
30. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
31. The role of the blood bank in transplantation.
McCullough J
Arch Pathol Lab Med; 1991 Dec; 115(12):1195-200. PubMed ID: 1768207
[TBL] [Abstract][Full Text] [Related]
32. Implementation of a configurable laboratory information management system for use in cellular process development and manufacturing.
Russom D; Ahmed A; Gonzalez N; Alvarnas J; DiGiusto D
Cytotherapy; 2012 Jan; 14(1):114-21. PubMed ID: 21973024
[TBL] [Abstract][Full Text] [Related]
33. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
34. Critical Care Network in the State of Qatar.
Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
[TBL] [Abstract][Full Text] [Related]
35. Concluding commentary on current trends to enhance the clinical safety of pediatric transfusion, focusing on prevention of untoward complications of HSC transplantation & newer strategies for improving the standards of safety/quality of stem cells expansion for cellular therapy.
Sniecinski I; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):378-383. PubMed ID: 29778713
[TBL] [Abstract][Full Text] [Related]
36. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
[TBL] [Abstract][Full Text] [Related]
37. Navigating the clinical trial pathway: Conception, design, execution, and results dissemination.
Sampalis JS; Watson J; Boukas S; Boukas M; Harvey N; Machado S; Bordeleau M; Rampakakis E
Surgery; 2017 Mar; 161(3):576-583. PubMed ID: 28190508
[TBL] [Abstract][Full Text] [Related]
38. Handling the different requirements for commercial and investigational MNC collections by apheresis.
Bobr A; Roberts T; Koepsell S; Williams SM; Schwartz J
Cytotherapy; 2024 Apr; ():. PubMed ID: 38703156
[TBL] [Abstract][Full Text] [Related]
39. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine.
Hillyer CD; Josephson CD; Blajchman MA; Vostal JG; Epstein JS; Goodman JL
Hematology Am Soc Hematol Educ Program; 2003; ():575-89. PubMed ID: 14633800
[TBL] [Abstract][Full Text] [Related]
40. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?
Chen LN; Collins-Johnson N; Sapp N; Pickett A; West K; Stroncek DF; Panch SR
Transfusion; 2019 Aug; 59(8):2506-2518. PubMed ID: 31135995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
